Skip To Main Content
Jeffrey Yin on Muck Rack

Jeffrey Yin

As seen in: Wiley Online Library, British Pharmacological Society
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeffrey

Contact Jeffrey, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis

|
By Selena Z Kuo, Jeffrey Yin, Rohit Loomba
| Wiley Online Library Verified
References 1 and , “Primary Biliary Cholangitis: Personalizing Second-Line Therapies,” Hepatology 82 (2024): 895–910, https://doi.org/10.1097/hep.0000000000001166. 2, , , , and , “Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases,” Hepatology 69, no. 1 (2019): 394–419.
Open in Who Shared Issue with article?

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

|
By Ruth Byrne, Jeffrey Yin, Nimish Patel, Tali Faggiano
| Wiley Online Library Verified
INTRODUCTION The use of long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) continues to expand as a treatment option for people with HIV as real-world data surrounding the effectiveness continue to accumulate [1, 2]. As an alternative to daily oral antiretroviral therapy (ART), LAI CAB/RPV is administered monthly or every 2 months.
Open in Who Shared Issue with article?

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease

|
By Luis Diaz, Jeffrey Yin, Rohit Loomba
| Wiley Online Library Verified
Conflicts of Interest R.L. serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics.
Open in Who Shared Issue with article?
See all 4 articles